Ajanta Pharma Limited — Important, 30-01-2025: Financial Result Updates

Ajanta Pharma Limited reported strong financial performance for the third quarter and nine months ended 31 December 2024.

For Q3 FY 2025, revenue from operations increased by 4% to ₹1,146 crore compared to ₹1,105 crore in Q3 FY 2024. The EBITDA rose by 2% to ₹321 crore, resulting in an EBITDA margin of 28%. Net profit for the quarter reached ₹233 crore, reflecting an 11% year-over-year growth from ₹210 crore, with an EPS of ₹18.60.

In the nine months ending December 2024, the company recorded a revenue surge of 10% to ₹3,478 crore, up from ₹3,155 crore the previous year. EBITDA grew by 8% to ₹962 crore, maintaining a steady margin of 28%. Net profit for this period was ₹695 crore, up 13% from ₹613 crore, with an EPS of ₹55.52.

Operational costs increased, with employee benefits expense up 21% YoY, reflecting investments in workforce expansion amidst expanding operations. The cost of materials consumed remained stable, indicating effective supply chain management.

The balance sheet showcased strong cash flow dynamics, with operating cash flow of ₹985 crore and free cash flow of ₹675 crore, underscoring effective working capital management.

Strategically, Ajanta Pharma continues to focus on enhancing its branded generics business, which accounted for a significant portion of revenues driven by growth in therapeutic segments like dermatology and pain management. Overall market sentiment remains favorable.

The financial outlook appears positive, supported by a consistent growth trajectory, effective cost management, and a robust product pipeline with numerous new launches anticipated. Given these factors, the stock presents a compelling case for a buy or hold consider potential risks in market fluctuations and operational expenses.